Precursor B Cell Receptor–Dependent B Cell Proliferation and Differentiation Does Not Require the Bone Marrow or Fetal Liver Environment by Rolink, Antonius G. et al.
 
23
 
J. Exp. Med. 
 
Ó
 
 The Rockefeller University Press • 0022-1007/2000/01/23/09 $5.00
Volume 191, Number 1, January 3, 2000 23–31
http://www.jem.org
 
Precursor B Cell Receptor–dependent B Cell Proliferation 
and Differentiation Does Not Require the Bone Marrow or 
Fetal Liver Environment
 
By Antonius G. Rolink,
 
*
 
 Thomas Winkler,
 
‡
 
 Fritz Melchers,
 
*
 
and Jan Andersson
 
*
 
From the 
 
*
 
Basel Institute for Immunology, CH-4005 Basel, Switzerland; and the 
 
‡
 
Department of 
Immunology, Friedrich-Alexander University, D-91054 Erlangen, Germany
 
Abstract
 
The capacity of precursor B (pre-B) I cells from fetal liver and bone marrow to proliferate and dif-
 
ferentiate into surface immunoglobulin–positive immature B cells in vitro
 
 
 
was analyzed. Both fetal
liver– and bone marrow–derived progenitors do so in a pre-B cell receptor (pre-BCR)–dependent
manner in tissue culture medium alone, without addition of other cells or cytokines. Approxi-
mately 20% of the initial pre-B I cells enter more than one division. Analyses at the single-cell
 
level show that 
 
z
 
15% divide two to five times. Coculture of pre-B I cells with stromal cells did
not enhance proliferation or differentiation, whereas the presence of interleukin 7, especially in
combination with stromal cells, resulted mainly in the expansion of pre-B I cells and prevented
their further differentiation. Thus, the environment of fetal liver or bone marrow is not required
for the pre-BCR to exert its function, which is to select and expand cells that have undergone an
inframe V
 
H
 
-D
 
H
 
J
 
H
 
 rearrangement that produces a pre-BCR–compatible 
 
m
 
H chain. It appears un-
likely that a ligand for the pre-BCR drives this pre-B cell proliferation.
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Introduction
 
The differentiation of precursor cells along the pathway
of B lymphocyte development from the most immature, B
lineage–committed progenitor to the antigen-sensitive, sur-
face immunoglobulin (sIg)
 
1
 
-expressing B cells takes place be-
fore birth mainly in the fetal liver, whereas the bone mar-
row is the major B cell–producing organ after birth (1).
This developmental process is characterized by changes in
the expression of intracellular and surface-bound molecular
markers, as well as by the status of Ig gene rearrangements
at the Ig heavy (H) and light (L) chain gene loci (2–4). The
precursor B cell receptor (pre-BCR), consisting of a 
 
m
 
H
chain associated with the surrogate light (SL) chain compo-
nents, V
 
pre-B
 
 and 
 
l
 
5
 
, plays a key role in this developmental
process. Thus, mice that cannot form a pre-BCR because
of a targeted inactivation of the 
 
l
 
5
 
 gene show a 10–20-fold
lower number of cytoplasmic 
 
m
 
H chain (c
 
m
 
)
 
1
 
 pre-B II
cells in their bone marrow compared with wild-type mice.
Therefore, the expression and formation of a pre-BCR
dramatically improve the efficiency of pre-B and B cell
production (5, 6), most likely by signaling proliferative ex-
pansion of pre-B cells.
We have shown previously with CD19
 
1
 
B220
 
1
 
c-kit
 
1
 
pre-B I cells, grown in vitro on stromal cells in the presence
of IL-7, that this stage of B cell development—character-
ized by DJ rearrangements, usually on both H chain alleles,
and surface expression of c-kit—can be maintained for long
periods of time. Thus, the combined action of IL-7 and
stromal cells prevented further differentiation into later stages
of B cell development. However, withdrawal of the growth
factor IL-7 resulted in the differentiation of these pre-B I
cells to sIgM
 
1
 
 immature B cells (7). Thus, differentiation is
an intrinsic property of pre-B I cells and does not require
the bone marrow or the fetal liver microenvironment. How-
ever, in this in vitro system, pre-B I cells from 
 
l
 
5
 
2
 
/
 
2
 
 mice
differentiate with the same efficiency as wild-type pre-B I
cells upon withdrawal of IL-7, indicating that the pre-BCR
is not involved in B cell differentiation.
Here, we analyze the in vitro differentiation potential of
ex vivo–isolated pre-B I cells. We find that pre-B I cells
derived from normal C57BL/6 (B6) bone marrow or fetal
liver spontaneously undergo proliferative expansion and
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differentiate into sIg
 
1
 
 immature B cells at high efficiencies
when placed in tissue culture. This in vitro proliferation
and differentiation process does not require any added cy-
tokines, or any other environmental factors or cells from bone
marrow or fetal liver. Pre-B I cells from 
 
l
 
5
 
2
 
/
 
2
 
 mice do not
undergo this proliferative expansion. Thus, the efficiency
by which the 
 
l
 
5
 
2
 
/
 
2
 
 pre-B I cells differentiate in vitro is poor.
Our data indicate that pre-B I cells isolated ex vivo from
normal mice possess an autonomous capacity to proliferate
and differentiate. It appears that the environment of fetal
liver or bone marrow is not required for the pre-BCR to
exert its major functions, namely, the selection and expan-
sion of cells that have undergone a productive V
 
H
 
-D
 
H
 
J
 
H
 
 re-
arrangement.
 
Materials and Methods
 
Mice
 
B6 mice were obtained from the Institut für Biologisch-
Medizinische Forschungs AG (Füllinsdorf, Switzerland). 
 
l
 
5
 
2
 
/
 
2
 
(5) backcrossed to B6 for five generations and 
 
E
 
m
 
–bcl-2
 
 trans-
genic B6 (8) mice were bred at the Institute’s animal facilities.
Mice of 4–6 wk of age were used.
 
FACS
 
®
 
 Staining and Sorting
 
Cell Surface Staining. 
 
Cells for FACS
 
®
 
 sorting were prepared
from adult bone marrow or fetal liver at day 17 or 18 of gestation
as described previously (7). In most experiments, cells were en-
riched for CD19
 
1
 
 cells using the SuperMACS high gradient mag-
netic cell separation system, following the protocol of the supplier
(Miltenyi Biotec). Cells enriched for CD19 expression were
stained with Cy5-conjugated mAb RA3 6B2 (anti-CD45R, B220)
and biotin-conjugated mAb ACK-4 (anti–c-kit [9]). The biotin-
conjugated mAb was visualized using streptavidin-PE (Southern
Biotechnology Associates, Inc.). CD19
 
1
 
B220
 
1
 
c-kit
 
1
 
 progenitor B
(pro-B) and pre-B I cells were sorted using the MoFlo
 
® 
 
high-speed
sorter (Cytomation, Inc.). 
 
PKH2-GL Labeling of Cells. 
 
Sorted CD19
 
1
 
B220
 
1
 
c-kit
 
1
 
 pro-
and pre-B I cells (5 
 
3 
 
10
 
5
 
–10
 
6
 
 cells) were washed once in PBS, and
then incubated for 2 min at room temperature with 4 
 
m
 
M PKH2-
GL in 200 
 
m
 
l PKH diluent A (Sigma Chemical Co.). To obtain a
homogeneously green fluorescent population, PKH2-labeled cells
were resorted in a narrow FL1 (green fluorescence) gate using the
MoFlo
 
®
 
 high-speed sorter. 
 
Sorting of Single Cells for Culture. 
 
Single cells were sorted us-
ing the FACStar
 
PLUS™
 
 equipped with an automatic cell deposition
unit (ACDU; Becton Dickinson), as described previously (10). 
 
Intracellular and Cell Surface Staining.
 
Cytoplasmic 
 
m
 
H protein
expression was detected as described previously (10). For cell sur-
face staining, the following mAbs were used: biotin- or FITC-con-
jugated M41 (anti-
 
m
 
 [11]), biotin-conjugated 1.19 (anti-
 
d
 
 [12]), bi-
otin-conjugated 187.1 (anti-
 
k
 
L chain [13]), and FITC-conjugated
anti-
 
l
 
L chain (clone R26-46, which recognizes 
 
l
 
1
 
 and 
 
l
 
2
 
 L chains;
PharMingen). Cell surface staining was performed as described pre-
viously (7, 14). Biotin-conjugated mAbs were visualized using
streptavidin-PE. Samples were analyzed on a FACSCalibur™
(Becton Dickinson).
 
Cell Culture
 
Sorted CD19
 
1
 
B220
 
1
 
c-kit
 
1
 
 cells, either labeled with PKH2-
GL or not, were cultured at 2 
 
3
 
 10
 
5
 
 cells per ml in IMDM me-
dium (GIBCO BRL) containing 5 
 
3
 
 10
 
2
 
5 
 
M 2-ME, 1
 
3
 
 nones-
sential amino acids (GIBCO BRL), 0.03% Primatone
 
®
 
 (Quest
International), and 2% FCS. Cells were cultured in flat-bottomed
96-well microtiter plates (Costar Corp.). In some experiments,
cells were cultured on irradiated (3,000 rad) ST-2 stromal cells
(15) as described previously (7). Recombinant IL-7 was produced
and used as described (16). At different time points, cells were
harvested and used for analysis. Viable cells were counted in a
light microscope using a Neubauer hemocytometer and the try-
pan blue dye exclusion test. Frequencies of LPS-reactive B cells
were determined by limiting dilution analyses in rat thymus filler
cells as described previously (16, 17). In some experiments, single
B220
 
1
 
c-kit
 
1
 
 cells were sorted directly into tissue culture me-
dium–containing round-bottomed microtiter plate wells using
the ACDU-equipped FACStar
 
PLUS™
 
. Cultures were scored daily
for growing clones, and the number of cells per clone was deter-
mined using a Diavert inverted light microscope (Leitz).
 
Results
 
In Vitro Differentiation of Ex Vivo–isolated B6 Bone Marrow–
or Fetal Liver–derived Pre-B I Cells.
 
Bone marrow and fetal
liver CD19
 
1
 
B220
 
1
 
c-kit
 
1
 
 pre-B I cells from B6 mice were
sorted, and the kinetics and efficiency of in vitro differenti-
ation were monitored by viable cell recovery, cytoplasmic
 
m
 
H chain and sIgM expression, and also by measurements
of cellular division. Moreover, the frequency of LPS-reac-
tive cells was determined both in the sorted starting popu-
lation and in the population recovered after 6 d of culture.
As shown for bone marrow (Fig. 1), sorted pre-B I cells
had a purity of 
 
.
 
95%. Approximately 10–20% of these
cells expressed 
 
m
 
H chains in their cytoplasm (i.e., are c
 
m
 
1
 
;
Fig. 1 and Fig. 2 C), whereas none of them had detectable
levels of sIgM (Fig. 2 C). Up until day 2 of culture, the
number of viable cells derived from bone marrow pre-B I
cells was found to be 
 
z
 
70–80% of the input number (Fig.
2 A). Thereafter, cell numbers steadily increased, reaching
values of two to three times that of the input number (Fig.
2 A). Similar findings were made with fetal liver–derived
pre-B I cell cultures (Fig. 2 A), with the difference that the
culture time required to reach numbers of cells exceeding
the input number was shortened by 1 d. Therefore, the
maximal number of cells that could be recovered at day 4
or 5 was slightly higher than that from cultured bone mar-
row cells. Thus, both bone marrow– and fetal liver–derived
pre-B I cells underwent proliferative expansion when placed
in tissue culture, and in an apparently growth factor–inde-
pendent fashion.
This conclusion was strengthened and extended by ex-
periments in which bone marrow– and fetal liver–derived
pre-B I cells labeled with the green fluorescent dye PKH2
were cultured. As shown in Fig. 2 B, the vast majority of
viable cells recovered at day 6 of culture had 8–16 times
less fluorescence intensity than the initial starting popula-
tion, indicating that these cells had undergone 3 or 4 divi-
sions. Note that practically no cells with the initial fluores-
cence intensity of the starting population of wild-type
pre-B I cells could be detected after 6 d of culture. In fact,
a time course experiment showed that cells with the initial 
25
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fluorescence intensity were not detectable starting from day
3 to 4 of culture. Since the maximal number of viable cells
recovered from these cultures is about two to three times
higher than the input number, and since these cells divided
an average of three to four times, we calculate that the cell
population recovered at day 6 of culture is derived from 15–
25% of the initially seeded pre-B I cells. Conversely, 75–85%
of CD19
 
1
 
B220
 
1
 
c-kit
 
1
 
 pro-/pre-B I cells of wild-type B6
mice fail to survive in culture, and are not amendable for
analyses that monitor differentiation of B lineage cells.
The differentiation potential of the pre-B I cells surviv-
ing our in vitro cultures was analyzed by monitoring the
expression of c
 
m
 
 and sIgM over time. As shown in Fig. 2 C,
for bone marrow– and fetal liver–derived pre-B I cells from
wild-type B6 mice, 10–20% of the starting c-kit
 
1
 
 cells are
already c
 
m
 
1
 
, but do not (or do not yet) express it at
FACS
 
®
 
-detectable levels on the surface. However, by day
3 or 4 of culture 
 
.
 
95% of all recovered cells are c
 
m
 
1
 
. Thus,
proliferative expansion and selection for inframe V
 
H
 
D
 
H
 
J
 
H
 
rearrangements takes place in tissue culture, as it normally
does in vivo in fetal liver or bone marrow (6). This also al-
lows the conclusion that the environment of the fetal liver
or the bone marrow is not required for this proliferation
and differentiation.
sIgM expression is first detectable at day 3 of culture.
sIgM
 
1
 
 cells reach maximal numbers of 
 
z
 
70% of all viable
cells for bone marrow– and 85% for fetal liver–derived pre-B
I cells at day 6 (Fig. 2 C). Moreover, double staining for
surface-expressed IgM/IgD and 
 
k
 
/
 
l
 
 L chains was per-
formed on cells after 5 d of culture. In Fig. 1 (lower dot
plots), results for bone marrow pre-B I cells are shown.
Cultures of fetal liver–derived pre-B I cells from wild-type
B6 mice showed an identical phenotype (data not shown).
About half of the sIgM1 B cells express low levels of IgM
and do not yet express IgD, whereas the other half express
high levels of IgM and low levels of IgD. Thus, with this in
vitro culture system, pre-B I cells can reach the stage of
“transitional B cells” (18). Moreover, the ratio of k/l L
chain–expressing cells is 20:1, i.e., similar to the ratio found
with immature and mature B cells in vivo.
The frequencies of B cells reactive to LPS and develop-
ing into clones of IgM-secreting cells were determined us-
ing limiting dilution assays. As shown in Fig. 2 D, freshly
ex vivo–isolated pre-B I cells from both bone marrow and
fetal liver of wild-type B6 mice yielded frequencies of z1/
50 to 1/200, whereas frequencies of z1/3 to 1/10 were
found with cells recovered after 6 d of culture. Thus, our in
vitro culture system allowed cells to reach the mature stage
of mitogen responsiveness in frequencies similar to wild-
type splenic B cells from B6 mice (17).
It is well established that IL-7 is a critical growth factor
for pro-/pre-B I cells (7, 19). Moreover, it has been sug-
gested that IL-7 might also play a role at later stages of B
cell differentiation (20). However, the proliferation and dif-
ferentiation of ex vivo–isolated pre-B I cells appear to be IL-7
independent. However, autocrine IL-7 production and/or a
contamination by IL-7–producing non–pre-B I cells in our
sorted pre-B I cell population cannot be completely ruled
out. Therefore, the in vitro proliferation and differentiation
of pre-B I cells in bulk as well as single cell cultures (see be-
low) were also tested in the presence of 10 mg/ml of an IL-7
receptor (IL-7R) a chain–specific mAb (clone A7R34 [21]).
This mAb concentration is known to completely block
IL-7–dependent growth of pre-B I cells in vitro (16, 21).
No influence on the frequency or clone size of growing
pre-B I cells, or on their capacity to mature into sIg1 cells,
could be observed (data not shown).
In Vitro Differentiation of Ex Vivo–isolated Pre-B I Cells from
l52/2 Mice. Selection and clonal expansion of inframe
VHDHJH-rearranged pre-B I cells are thought to be medi-
ated by the pre-BCR (5, 6, 10). Hence, pre-B I cells from
l5
2/2 mice, i.e., from mice that cannot form a proper pre-
BCR, should not proliferate in our cultures if the observed
proliferation was pre-BCR dependent. Fig. 2 shows the re-
Figure 1. Sorting and phenotypic analyses of bone
marrow pre-B I cells. Bone marrow cells from B6 mice
were depleted of sIg1 cells by magnetic separation, but
not enriched for CD191 cells, and thereafter double
stained with Cy5-labeled anti-B220 and biotin-labeled
anti–c-kit for sorting (top left) and reanalyses of sorted
cells (top middle). Staining for CD19-expressing cells
revealed .95% positive cells (data not shown). Some
of the sorted cells were permeabilized and stained with
a polyclonal FITC-labeled goat anti-IgM for deter-
mination of cm chain content (top right). After 5 d of
culture, viable cells were double stained for surface
IgM/IgD (bottom left) and surface k/l L chains (bot-
tom right).26 Pre-BCR–dependent B Cell Differentiation In Vitro
sults with ex vivo–isolated bone marrow pre-B I cells from
l5
2/2 mice. When l5
2/2 pre-B I cells were cultured, a rapid
loss of viable cells was observed. By day 4 of culture, hardly
any (z5% of input) viable cells could be recovered (Fig. 2 A).
Moreover, no cellular division took place in these cultures.
This conclusion is based on the results obtained with the
l5
2/2 pre-B I cells labeled with the green fluorescent dye
PKH2. As shown in Fig. 2 B, the low number of cells that
could be recovered at day 4 of culture still had the same
fluorescence intensity as the starting population. Identical
results were obtained with day 17 or 18 fetal liver pre-B I
cells from l5
2/2 mice.
Differentiation of l5
2/2 pre-B I cells in culture was
monitored by determining the frequencies of cm1 and
sIgM1 cells with time. Like ex vivo–isolated B6 pre-B I
cells, z20% of the ex vivo–isolated l5
2/2 pre-B I cells ex-
pressed a mH chain in the cytoplasm. By day 4, this percent-
age increased twofold (Fig. 2 C). However, the absolute
number of viable cells had dropped z20-fold (Fig. 2). Ap-
proximately 10% of the remaining cells were sIgM1 at day
3 or 4 of culture (Fig. 2 C). Thus, in contrast to wild-type
pre-B I cells, l5
2/2 pre-B I cells differentiate with very low
efficiencies when cultured in vitro. This is also seen in the low
frequency of LPS-reactive cells obtained from the starting
population of l5
2/2 pre-B I cells, which is z30-fold lower
than that observed with wild-type pre-B I cells (Fig. 2 D).
Thus, the formation of a pre-BCR is a necessary prerequi-
site for selection, proliferative expansion, and survival of cells
with an in-frame VDJ-rearranged mH chain.
Efficient In Vitro Proliferation of Single Pre-B I Cells.
Since in vitro proliferation and differentiation of pre-B I
cells is dependent on the capacity to express a pre-BCR,
the question arises of whether a ligand is required to inter-
act with the pre-BCR. Since the experiments described
Figure 2. Proliferation and differentiation of sorted pre-B I cells. CD191B2201c-kit1 pre-B I cells from bone marrow (BM) and day 17 fetal liver (FL)
of wild-type, bone marrow of l5
–/–, and bone marrow of bcl-2 transgenic B6 mice. (A) Viable cell recovery. (B) Cellular division as revealed by the de-
crease of PKH2 fluorescent intensity after 6 d (wild-type B6 bone marrow and fetal liver and bcl-2 transgenic bone marrow) or 4 d (B6 l5
2/2 bone mar-
row) of culture (dotted line), compared with the intensity of the starting population (solid line histogram). (C) Expression of cytoplasmic mH chain (h)
and sIgM (s). (D) LPS reactivity before (s) and after (h) 6 d of culture as analyzed by limiting dilution analysis.27 Rolink et al.
above were all performed in bulk cultures at 2 3 105 pre-B I
cells per milliliter, it could not be excluded that a ligand on
a neighboring cell might interact with the pre-BCR on the
pre-B cell. Therefore, single pre-B I cells from wild-type
B6 bone marrow were sorted directly into 96-well round-
bottomed microtiter plates containing 0.2 ml plain culture
medium without any growth factors or feeder/stromal cells.
By day 5 of culture, the potential of single pre-B I cells to
proliferate was recorded using an inverted microscope.
Wells containing four or more cells were scored positive.
From 672 individual cells plated, 99 showed growing clones
with 4 or more cells (14.8%). As shown in Fig. 3 A, z33%
of cultures with growing clones contained only 4 cells,
whereas the others contained 8, 16, or 32 cells, and 1 even
contained 64 cells. In the highest percentage of cultures
containing .4 cells at day 5, z16 cells were found. This
suggests that these pre-B cells had undergone four divisions.
In Fig. 3 B, microphotographs of one clone of z32 cells,
and another with 8 cells, are shown. Thus, the frequency of
single pre-B I cells that undergo proliferative expansion, as
well as the efficiency by which they divide, is similar to that
observed in bulk cultures (Fig. 2, A and B). The fact that a
single pre-B I cell can proliferate in the absence of any other
cell argues against a potential ligand presented by a neigh-
boring cell to the pre-BCR. In fact, these experiments also
make it unlikely that a soluble ligand for a pre-BCR exists.
In Vitro Differentiation of Pre-B I Cells Expressing a bcl-2
Transgene. The results described previously (Fig. 2 B) showed
that all cells recovered at day 6 from cultures of wild-type
B6–derived pre-B I cells were cm1 and had divided three
or four times, and thus represented only 15–25% of the
originally plated c-kit1 population. Consequently, 75–85%
of wild-type B6–derived pre-B I cells must have died dur-
ing culture. This inability to proliferate and survive may
have been due to out-of-frame VDJ rearrangements at the
mH chain locus, resulting in cells not producing a mH chain,
or may have been the consequence of a mH chain unable
to pair with an SL chain.
To analyze the pre-B I population, which does not nor-
mally survive upon in vitro culture, we took advantage of
the fact that overexpression of an Em-controlled bcl-2 trans-
gene early in B cell development allows prolonged survival
of pro- and pre-B cells (8, 22). Thus, experiments identical
to those presented in Fig. 2 for wild-type B6–derived pre-B
I cells were performed with pre-B I cells isolated from bcl-2
transgenic B6 mice. The results are shown in Fig. 2. Pre-B
I cells expressing a bcl-2 transgene proliferate when placed
in culture, as 3.5 times the number of initially plated cells
could be recovered at day 6. Moreover, these cells also dif-
ferentiated so that z80% of the cells at day 3 or 4 of culture
became cm1 cells (Fig. 2 C). However, in contrast to non-
transgenic cells, not all bcl-2 transgenic cells developed to
cm1 cells. Approximately 20% of the viable cells recovered
at day 6 or 7 of culture were found to be cm2 (Fig. 2 C).
Also, sIgM1 cells only developed to z60–70% of all cells in
culture at day 6 (Fig. 2 C). Comparable results were ob-
tained using fetal liver–derived pre-B I cells expressing the
same bcl-2 transgene.
bcl-2–expressing pre-B I cells developed LPS reactivity at
similar frequencies to wild-type pre-B I cells. Thus, ex
vivo–isolated bcl-2 transgenic pre-B I cells yielded frequen-
cies of LPS-reactive cells of z1/50 to 1/80, whereas in 1/3
Figure 3. Clonal growth of single CD191B2201c-kit1 pre-B I cells.
Single pre-B I cells were sorted from bone marrow of wild-type B6 mice
and grown for 5 d, at which time cultures containing more than two cells
were considered to be growing, and the number of cells per clone was
determined. (A) The data are presented as a histogram of the percentage
of growing clones with a given size (4, 8, 16, or 32 cells). However, not
all cultures containing growing clones have this exact number of cells, but
fall around that value, allowing us to categorize a given clone. (B) 2 dif-
ferent representative clones from the above experiment are shown, one
with 32 cells, and the other containing 8 cells.28 Pre-BCR–dependent B Cell Differentiation In Vitro
to 1/5 cells, the cells recovered after 6 d of culture were re-
sponsive to LPS (Fig. 2 D).
When pre-B I cells were labeled with the green fluores-
cent dye PKH2, and subsequently recorded for their fluo-
rescence intensity with time in culture, the majority of
growing bcl-2 transgenic pre-B cells, like wild-type pre-B
cells, lost fluorescence intensity, indicating that they under-
went several divisions during the 6-d culture period (Fig. 2).
As can be seen in the histogram, the population of bcl-2
transgenic cells that exhibits a decrease in fluorescence in-
tensity is more heterogeneous than that of the correspond-
ing wild-type pre-B cells, indicating a larger heterogeneity
in clone sizes among the dividing cells. However, unlike
wild-type pre-B I cells, z20–25% of the cells recovered at
day 6 still had the same fluorescence intensity as the starting
population, indicating that these cells did not divide (Fig. 2 B).
Based on the absolute number of cells that could be recov-
ered at day 6 of culture, the 20–25% nondividing cells rep-
resented z70% of the initially seeded population. This per-
centage was close to the calculated percentage of wild-type
nontransgenic pre-B I cells that were found to die during
the same culture period (75–85%).
At day 6 of culture, sIgM expression of PKH2-labeled
pre-B I cells was monitored. As shown in Fig. 4, a large pro-
portion (.40%) of the cells that had divided became sIgM1,
whereas only 10% (representing z2% of the total popula-
tion) of the cells that did not divide were sIgM1. We con-
clude from these experiments that mH chain–expressing
pre-B cells divide, whereas mH chain–negative cells do not
in our cultures, which do not contain cytokines or growth-
supporting cells.
The Effects of Stromal Cells and/or IL-7 on the In Vitro Dif-
ferentiation of Pre-B I Cells. To test for the effects of stro-
mal cells and/or IL-7 on the in vitro proliferation and
differentiation of pre-B I cells, we repeated the above ex-
periments, now also including these essential components of
the bone marrow microenvironment. Thus, ex vivo–sorted
pre-B I cells from bone marrow of B6 and l5
2/2 mice
were cultured for 4 d in the presence or absence of stromal
cells and/or recombinant mouse IL-7. In Fig. 5, the results
of a representative experiment are shown. No differences
were detected between culturing pre-B I cells with or with-
out stromal cells in the absence of IL-7. Thus, both culture
conditions resulted in a 2.5-fold increase of viable cells at
day 4 with B6-derived pre-B I cells, whereas in the case of
l5
2/2 pre-B I cells, ,10% of the initially plated cells could
be recovered at day 4. In fact, this very low cellular recov-
ery did not allow any further FACS® analyses of these cells.
In the case of B6 pre-B I cells, both culture conditions re-
sulted in similar high efficiency development (.90%) of
cm1 cells. Moreover, only 10% of the cells recovered at day
4 still express c-kit on their surface, whereas up to 40% of
them express sIgM. Thus, the presence of stromal cells does
not improve the proliferative capacity or the efficiency of
differentiation of B6 or l5
2/2 pre-B I cells.
In the presence of IL-7, z10–15 times the number of
input cells could be recovered at day 4 from both B6 and
l5
2/2 pre-B I cell cultures. Among the B6-derived cells,
z60% express mH chains in their cytoplasm, whereas 40%
of the l5
2/2 cells do so. Approximately 50% of B6-derived
cells still express c-kit at day 4 of culture, whereas .80% of
the l5
2/2-derived cells do so. Thus, the presence of IL-7 in
these cultures prevents the downregulation of c-kit and the
expression of cm, and enhances the proliferation indepen-
dently of the expression of l5.
Cell sIgM expression was detectable on 15% of the B6
cells grown in IL-7–containing medium, whereas no sIgM-
expressing cells developed among l5
2/2-derived cells grown
in the same way. Thus, the presence of IL-7 in these cul-
tures results in the proliferation of pre-B I cells, and also in
part in their differentiation into cm1 and sIgM1 B cells.
This differentiation seems to be pre-BCR dependent, since
it is far less pronounced in cultures initiated with l5
2/2
pre-B I cells. However, from these experiments it is hard to
deduce whether IL-7 is only a growth factor for pre-B I
cells, or is also involved in their differentiation.
It is also evident from the results presented in Fig. 5 that
the combined action of stromal cells and IL-7 on both nor-
mal and l5
2/2 pre-B I cells enhances their proliferation, re-
sulting in a 25–50-fold increase of viable cells at the end of
the 4-d culture period. As has been published previously
(7), these culture conditions prevent the further differentia-
tion of these cells, and maintain the expanding proliferating
cells at the c-kit1 pre-B I stage of B cell development.
Figure 4. Phenotypic analyses of dividing and nondividing pre-B cells.
Sorted pre-B I cells from bone marrow of bcl-2 transgenic B6 mice were
labeled with the green fluorescent dye PKH2-GL and cultured in vitro
for 6 d. For analyses of sIgM, cells were stained with biotin-labeled M41
revealed by PE-labeled streptavidin. The top histogram shows cells that
have undergone proliferation (Cycling) with decreased PKH2 green fluo-
rescent intensity, and those expressing the same high PKH2 intensity
(Non cycling) as the initially seeded population (see also Fig. 2 B). By gat-
ing on PKH2 high and low, respectively, after staining for sIgM, the bot-
tom two histograms were obtained.29 Rolink et al.
Discussion
We have presented experimental evidence in this paper
that 15–25% of c-kit1 pre-B cells can divide two to five
times in tissue cultures that do not contain cytokines or
supporting stromal cells. Since only wild-type and not l5
2/2
pre-B cells proliferate, division of pre-B cells at this stage of
development appears to be dependent on the expression of
a pre-BCR. Proliferation of pre-B cells at this stage of de-
velopment has been seen previously in fetal liver organ cul-
tures (16). The time course and extent of proliferation in
the cytokine- and stromal cell–free tissue cultures presented
in this paper are very similar to those seen previously in fe-
tal liver organ cultures, and both types of tissue cultures re-
quired the expression of a pre-BCR for proliferation. Since
we show in this paper that pre-B cells from both bone mar-
row and fetal liver require pre-BCR expression for prolif-
eration, our results contradict those of Hardy et al. (23),
which suggested that the pre-BCR controls proliferative
expansion of pre-B cells only in bone marrow, and not in
fetal liver.
It is well documented that IL-7 plays an essential role in
both T and B cell development in mice (19, 24, 25). The
IL-7– as well as the IL-7R–deficient mice show a block in
B cell development at a stage we would refer to as pro-/
pre-B I. Thus, the IL-7/IL-7R system seems to be essential
for the formation of a pre-B I compartment. However,
whether IL-7 could also play a role in later stages of B cell
development is far less clear. Our results presented here show
that CD191B2201c-kit1 pre-B I cells derived from a mouse
that can form a pre-BCR, and which produce IL-7 and ex-
press the IL-7R, do not require IL-7 for their in vitro dif-
ferentiation. However, we cannot exclude the possibility
that IL-7 might improve this differentiation by inducing a
better proliferation and/or survival of selected, cm-express-
ing pre-B II cells. The findings made with pre-B I cells from
B6 mice cultured in the presence of IL-7 alone (Fig. 5)
might support this possibility. Moreover, preliminary data
have indicated that IL-7 can act as a growth factor for large
pre-B II cells (Rolink, A.G., unpublished observations).
Also, a recent study using IL-7 transgenic mice indicates a
possible role for IL-7 at this stage of B cell development
(26). However, it is also evident from our results presented
in Fig. 5 that the combined action of IL-7 and stromal cells
Figure 5. The effects of stromal cells
and/or IL-7 on proliferation and differentia-
tion of bone marrow–derived pre-B I cells.
Bone marrow pre-B I cells from adult B6
and l5
2/2 mice were sorted as described in
the legend to Fig. 1, but after enrichment
for CD191 cells. Sorted cells were plated at
2 3 105 cells per ml in medium alone or on
3,000 rad–irradiated ST-2 stromal cells, or
at 5 3 104 cells per ml in medium contain-
ing 100 U/ml of recombinant mouse IL-7
in the absence or presence of 3,000 rad–
irradiated ST-2 stromal cells, as indicated.
After 4 d of culture, cells were harvested
and viable cell counting (A), cell surface
staining (C and D), and cytoplasmic staining
(B) for indicated markers were performed as
described in Materials and Methods.30 Pre-BCR–dependent B Cell Differentiation In Vitro
selectively induces proliferation of pre-B I cells, preventing
their differentiation into sIgM-expressing cells.
The c-kit1 pre-B cells that express mH chains in their
cytoplasm can be considered to be the transitional cells at
the stage between DHJH-rearranged pre-B I cells and large
VDJ/DJ or VDJ/VDJ-rearranged pre-B II cells in the bone
marrow of a mouse (10). Our previous analyses of the
structures of the mH chains initially produced at the transi-
tion from pre-B I to pre-B II cells in these c-kit1cm1 cells
have shown that approximately half of all the mH chains
cannot pair with SL chains to form a pre-BCR (10). Thus,
of the 10–20% of the c-kit1 precursor cells that are cm1,
only half (i.e., 5–10%) can form a pre-BCR. These 5–10%
of cells may well all take part in the proliferative expansion
observed in our in vitro cultures. Since these cells already
express a mH chain before our ex vivo isolation, it cannot
be ruled out that they have initiated their entry into the cell
cycle in vivo. However, our data show that 15–25% of the
original ex vivo–isolated pre-B I cells take part in the in
vitro proliferative expansion. Therefore, at least half of the
cells that proliferate in vitro had at the time of isolation not
yet detectable levels of mH chain expression, or had not yet
undergone a productive VDJ rearrangement so as to pro-
duce a pairing mH chain. We have shown previously that the
majority of bone marrow c-kit1 pre-B I cells has their IgH
loci in DJ/DJ–rearranged configuration (3). Moreover, pre-B
I cells grown in vitro on stromal cells in the presence of IL-7
can undergo V to DJ rearrangement upon withdrawal of
IL-7 (7). Therefore, we favor the idea that at least some of
the cells that underwent the pre-BCR–dependent in vitro
proliferation were not yet VDJ rearranged at the time of ex
vivo isolation, but became so during in vitro culture. Since
we have not yet identified a cell surface marker that distin-
guishes pre-B I cells with VDJ-rearranged IgH alleles, ei-
ther expressing a mH chain or not, from those pre-B I cells
that have both IgH alleles DJ rearranged only, full proof for
this idea is still lacking.
In particular, the single cell experiments presented here
show that not all c-kit1cm1 pre-B cells enter proliferative
expansion to the same extent. It is very possible that the
extent of proliferative expansion depends on the fitness of
the pre-BCR, i.e., on the avidity of a given mH chain to pair
with the SL chains (27). However, the experiments pre-
sented here cannot distinguish between well-pairing, loosely
pairing, and nonpairing mH chains. Since we can clone the
expressed mH chain gene from single pre-B cell clones, we
should be able to design experiments to test this avidity of
pairing in relation to the extent of proliferative expansion
exhibited by a single clone of cells.
From the data presented here, it appears clear that no cy-
tokine and no stromal cell support are needed for the two
to five cell divisions that occur in the in vitro cultures of
these cells. It is also likely that the pre-BCR does not need
to be occupied by a special ligand to exert its effect of con-
tinuous stimulation through the next two to five rounds of
division of a wild-type, but not a l5
2/2 pre-B cell, unless
one expects the FCS or the plastic of the tissue culture plates
to contain such ligands. Again, however, our experiments
do not completely rule out the possibility that such a ligand
might have been present in vivo before ex vivo isolation of
the cells. Since there is no experimental evidence for a ligand
for pre-BCR at this time, we favor the idea that a pre-B cell
senses the fitness of the interaction of a mH chain with SL
chains that might guide the assembly of the pre-BCR with
Iga, Igb, and other signal-transducing molecules in the sur-
face membrane (28), and conveys a sense of stability and sig-
nals for entry into the proliferative cycle to the pre-B cell.
The experiments with bcl-2 transgenic pre-B cells show
that the majority of sIgM1 cells that appear during culture
are derived from cells that underwent proliferative expan-
sion, whereas only a very small fraction (z10%, represent-
ing z5% of the total sIgM1 cells that appear in these cul-
tures) of nonproliferating cells express sIgM. This finding,
together with the finding that l5
2/2 pre-B cells did not
proliferate, provides strong support for the notion that the
pre-BCR is required for proliferative expansion at this stage
of development. Moreover, the finding that a bcl-2 transgene
allows the survival of those 80% of ex vivo–isolated pre-B I
cells that do not undergo proliferative expansion now also
makes it possible to analyze the fate of those VDJ-rearranged
pre-B cells that produce a mH chain that cannot form a
pre-BCR.
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